School of Medicine - Clinical MedicineRegenerative Medicine



The Regenerative Medicine Center at Kanazawa Medical University Hospital has been running since April, 2015, and the Department of Regenerative Medicine was established in July, 2016. As one of the medium-term plans of Kanazawa Medical University, we are carrying out the project known as “Regenerative Medicine and Cell Therapy Promotion”. In accordance with the Good Gene, Cellular, and Tissue-based Products Manufacturing Practice (GCTP) standards, the Regenerative Medicine Center conducts advanced research and development into the technology for regenerative medicine, transplant medicine, gene therapy, and cancer immunotherapy. We conduct clinical studies as well as treat patients at our medical facilities. We are promoting the development of dendritic cell (DC)-based cancer immunotherapy, collaborating with specialists of every field of oncology. We aim to establish therapeutic vaccinations with active DCs under a legal framework with optimization of DC vaccines as add-ons to chemotherapeutic drugs and/or radiotherapy to predict potential biomarkers of response. We also promote multicenter phase II clinical trials covered by the Advanced Medical Care System which are conducted on DC vaccines for advanced cancers. Treatment skills like these can contribute to the development of personalized therapies in cancer patients. The Department of Regenerative Medicine also promotes an education program for developing specialists in cell therapies and regenerative medicine.

Contact Information

TEL: 076-286-2211(内線8240) +81-76-218-8304 / FAX: 076-218-8364 / Email:


Professor and Chair

  • SHIMODAIRA Shigetaka

Senior Assistant Professor

  • KATOU Tomohisa

Assistant Professor

  • KOYA Terutsugu
  • SAKAMOTO Takuya


  • TOGI Misa

Research Achievements

Research Activities

  • Hirabayashi K, Yanagisawa R, Saito S, Higuchi Y, Koya T, Sano K, Koido S, Okamoto M, Sugiyama H, Nakazawa Y, Shimodaira S. Feasibility and immune response of WT1 peptide vaccination in combination with OK-432 for paediatric solid tumors. Anticancer Res 38(4): 2227-2234, 2018.
  • Yanagisawa R, Koizumi T, Koya T, Sano K, Koido S, Nagai K, Kobayashi M, Okamoto M, Sugiyama H, Shimodaira S. WT1-pulsed dendritic cell vaccine combined with chemotherapy for resected pancreatic cancer in a phase I study. Anticancer Res 38(4): 2217-2225, 2018.
  • Koya T, Yanagisawa R, Higuchi Y, Sano K, Shimodaira S. Interferon-ɑ-inducible dendritic cells matured with OK-432 exhibit TRAIL and Fas ligand pathway-mediated killer activity. Sci Rep. 7:42145. 2017.
  • Takahashi H, Shimodaira S, Ogasawara M, Ota S, Kobayashi M, Abe H, Morita Y, Nagai K, Tsujitani S, Okamoto M, Suzuki Y, Nakanishi Y, Yonemitsu Y; DC Vaccine Study Group at the Japanese Society of Immunotherapy and Cell Therapy. Lung adenocarcinoma may be a more susceptive subtype to a dendritic cell-based cancer vaccine than other subtypes of non-small cell lung cancers: a multicenter retrospective analysis. Cancer Immunol Immunother. 65(9):1099-111, 2016.
  • Shimodaira S, Sano K, Hirabayashi K, Koya T, Higuchi Y, Mizuno Y, Yamaoka N, Yuzawa M, Kobayashi T, Ito K, Koizumi T. Dendritic cell-based adjuvant vaccination targeting Wilms’ tumor1 in patients with advanced colorectal cancer. Vaccines. 3(4): 1004-1018, 2015.